Introduction: Testicular neoplasms are diseases that originate from germ cells, and their treatment consists of orchiectomy followed by chemotherapy or radiotherapy. Although this type of cancer generally has a good prognosis, some patients experience symptoms that affect their quality of life, such as nausea and vomiting. Objective: To describe the case of a patient in palliative care, diagnosed with metastatic testicular neoplasm, who presented with severe nausea and vomiting requiring five classes of antiemetics for symptom control. Case Report: M.R.C., 22 years old, farmer, Catholic, married, born and residing in Bragança, Pará. The patient began experiencing lower back pain radiating to the left lower limb in February 2024, which worsened with physical exertion and did not improve with the use of analgesics. In May 2024, he underwent a left orchiectomy following inguinal trauma, after which he developed abdominal pain associated with nausea and vomiting that progressively worsened since July 2024. During this period, he reported constipation, melena, and a weight loss of ten kilograms since the onset of the pain. He denied other comorbidities and was unable to provide information on family medical history. On physical examination, the patient reported pain on palpation of the left flank and hypogastric region, with a hardened, palpable mass of approximately 10 centimeters in the epigastric region. Abdominal MRI revealed a solid retroperitoneal lesion measuring 15 x 9.6 centimeters. The patient progressed with constipation, neuropathic pain, and a difficult-to-control episode of nausea and vomiting due to tumor compression. The antiemetic therapy used aimed to inhibit different pathways of nausea. Initially, dopamine and serotonin receptor antagonists with gastrointestinal action (Bromopride and Ondansetron, respectively) were administered to provide prokinetic effects and reduce vagal stimulation. Subsequently, central-acting dopamine receptor blockers (Haloperidol and Chlorpromazine) were added as adjuncts to the therapy, also contributing to the reduction of vagal activation. Finally, Dexamethasone was introduced to reduce inflammation and edema, as well as to enhance the effects of the other antiemetics. After optimizing the five-drug regimen, the patient showed clinical improvement, with a reduction in both the frequency and intensity of nausea episodes. Conclusion: Palliative care played a crucial role in managing nausea and vomiting. After implementing non-pharmacological measures such as dietary counseling, medications were gradually introduced and optimized to their maximum doses, at which point a new drug was added to the regimen. With the maintenance of the five-drug antiemetic therapy, the patient achieved adequate control of nausea and vomiting, significantly improving his quality of life and creating a more favorable context to continue his oncologic treatment.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
